Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older.
Pathfinders Neuromuscular Alliance are hosting a Natural Nutrition event on Monday 15th March at 1pm.
Shielding guidance for those who are clinically extremely vulnerable has been extended now until the 31st March 2021, instead of the previous date given 21st February 2021.
This morning we have received an update from NHS England making it easier to understand who is and isn’t eligible for treatment under the EAMS programme.
TreatSMA are today representing the community at the NICE appraisal of the first Gene Therapy for SMA, Zolgensma (onasemnogene abeparvovec-xioi).
TreatSMA have launched a new Facebook group called TreatSMA‘s Professional Therapy Group.